Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluzoparib with or without ADT as neoadjuvant therapy for HRR-abnormal high-risk localized prostate cancer
ChiCTR2000035193Phase 2Recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of fluzoparib in prostate cancer (PCa) (3 arms), sponsored by Chinese PLA General Hospital. Primary endpoint: pathologic complete response rate. Started Aug 2020; status: recruiting.
02
Drugs
fluzoparib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on ChiCTR2000035193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000035193.